Literature DB >> 24488785

The role of PML in hematopoietic and leukemic stem cell maintenance.

Fumio Nakahara1, Cary N Weiss, Keisuke Ito.   

Abstract

The tumor suppressor promyelocytic leukemia (PML) was first identified as a component of PML-RARα fusion protein, one of the initiating cytogenetic abnormalities in acute promyelocytic leukemia. PML is now known to have diverse functions regulating the DNA-damage response, apoptosis, senescence, and angiogenesis. Recent investigations have identified PML as a regulator of metabolic pathways in stem cell compartments, including the hematopoietic system, and have provided researchers with new strategies for controlling stem cell maintenance and differentiation. Studies of PML in leukemia-initiating cells demonstrate that PML is also an essential component of their maintenance, which has drawn tremendous attention to PML from scientists in various stem cell fields. Here, we review research into PML and its associated pathways, including recent studies of PML as it relates to stem cell biology, as well as our finding that PML regulates fatty acid oxidation, which is essential to the maintenance of normal hematopoietic stem cells. We also discuss the therapeutic potential of controlling PML-associated pathways. In particular, we describe promising evidence for the use of arsenic trioxide in the treatment of chronic myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24488785      PMCID: PMC4096053          DOI: 10.1007/s12185-014-1518-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  59 in total

1.  PTEN maintains haematopoietic stem cells and acts in lineage choice and leukaemia prevention.

Authors:  Jiwang Zhang; Justin C Grindley; Tong Yin; Sachintha Jayasinghe; Xi C He; Jason T Ross; Jeffrey S Haug; Dawn Rupp; Kimberly S Porter-Westpfahl; Leanne M Wiedemann; Hong Wu; Linheng Li
Journal:  Nature       Date:  2006-04-23       Impact factor: 49.962

Review 2.  Cellular metabolism and disease: what do metabolic outliers teach us?

Authors:  Ralph J DeBerardinis; Craig B Thompson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 3.  Roles of the hypoxia response system in hematopoietic and leukemic stem cells.

Authors:  Keiyo Takubo; Toshio Suda
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

Review 4.  Effects of hypoxia and HIFs on cancer metabolism.

Authors:  Vera Mucaj; Jessica E S Shay; M Celeste Simon
Journal:  Int J Hematol       Date:  2012-04-27       Impact factor: 2.490

5.  Identification of a tumour suppressor network opposing nuclear Akt function.

Authors:  Lloyd C Trotman; Andrea Alimonti; Pier Paolo Scaglioni; Jason A Koutcher; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Nature       Date:  2006-05-07       Impact factor: 49.962

6.  All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4).

Authors:  Harry J Iland; Ken Bradstock; Shane G Supple; Alberto Catalano; Marnie Collins; Mark Hertzberg; Peter Browett; Andrew Grigg; Frank Firkin; Amanda Hugman; John Reynolds; Juliana Di Iulio; Campbell Tiley; Kerry Taylor; Robin Filshie; Michael Seldon; John Taper; Jeff Szer; John Moore; John Bashford; John F Seymour
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

7.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells.

Authors:  Omer H Yilmaz; Riccardo Valdez; Brian K Theisen; Wei Guo; David O Ferguson; Hong Wu; Sean J Morrison
Journal:  Nature       Date:  2006-04-05       Impact factor: 49.962

8.  Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity.

Authors:  Vikram Mathews; Biju George; Kavitha M Lakshmi; Auro Viswabandya; Ashish Bajel; Poonkuzhali Balasubramanian; Ramachandran Velayudhan Shaji; Vivi M Srivastava; Alok Srivastava; Mammen Chandy
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 9.  Otto Warburg's contributions to current concepts of cancer metabolism.

Authors:  Willem H Koppenol; Patricia L Bounds; Chi V Dang
Journal:  Nat Rev Cancer       Date:  2011-04-14       Impact factor: 60.716

10.  A metabolic prosurvival role for PML in breast cancer.

Authors:  Arkaitz Carracedo; Dror Weiss; Amy K Leliaert; Manoj Bhasin; Vincent C J de Boer; Gaelle Laurent; Andrew C Adams; Maria Sundvall; Su Jung Song; Keisuke Ito; Lydia S Finley; Ainara Egia; Towia Libermann; Zachary Gerhart-Hines; Pere Puigserver; Marcia C Haigis; Elefteria Maratos-Flier; Andrea L Richardson; Zachary T Schafer; Pier P Pandolfi
Journal:  J Clin Invest       Date:  2012-08-13       Impact factor: 14.808

View more
  6 in total

Review 1.  A new transcriptional variant and small azurophilic granules in an acute promyelocytic leukemia case with NPM1/RARA fusion gene.

Authors:  Tomoe Kikuma; Yuji Nakamachi; Yoriko Noguchi; Yoko Okazaki; Daisuke Shimomura; Kimikazu Yakushijin; Katsuya Yamamoto; Hiroshi Matsuoka; Hironobu Minami; Tomoo Itoh; Seiji Kawano
Journal:  Int J Hematol       Date:  2015-09-05       Impact factor: 2.490

2.  Arsenite inhibits the function of CD133+ CD13+ liver cancer stem cells by reducing PML and Oct4 protein expression.

Authors:  Huaming Tang; Yukai Jin; Shilong Jin; Zhiming Tan; Zhang Peng; Yuanli Kuang
Journal:  Tumour Biol       Date:  2016-08-12

3.  Microtubule-associated protein 1 light chain 3 interacts with and contributes to growth inhibiting effect of PML.

Authors:  Wei He; Chuan-Xi Hu; Jia-Kai Hou; Li Fan; Yi-Wei Xu; Man-Hua Liu; Shu-Yang Yan; Guo-Qiang Chen; Ying Huang
Journal:  PLoS One       Date:  2014-11-24       Impact factor: 3.240

4.  Promyelocytic Leukemia Protein Is an Essential Regulator of Stem Cell Pluripotency and Somatic Cell Reprogramming.

Authors:  Christiana Hadjimichael; Konstantina Chanoumidou; Christoforos Nikolaou; Antonios Klonizakis; Gesthimani-Ioanna Theodosi; Takis Makatounakis; Joseph Papamatheakis; Androniki Kretsovali
Journal:  Stem Cell Reports       Date:  2017-04-06       Impact factor: 7.765

Review 5.  PML Bodies in Mitosis.

Authors:  Anna Lång; Emma Lång; Stig Ove Bøe
Journal:  Cells       Date:  2019-08-14       Impact factor: 6.600

Review 6.  The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.

Authors:  Sabrina Crivellaro; Giovanna Carrà; Cristina Panuzzo; Riccardo Taulli; Angelo Guerrasio; Giuseppe Saglio; Alessandro Morotti
Journal:  BMC Cancer       Date:  2016-05-16       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.